Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Viatris Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of VTRS revenue | Skew |
|---|---|---|---|
| TBPHTheravance Biopharma, Inc. | 35.00% | 0.26% | 133× |
| MCKMcKesson Corporation | 0.35% | 10.00% | 28× |
| CAHCardinal Health, Inc. | 0.28% | 5.00% | 18× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Cencora, Inc. (formerly AmerisourceBergen Corporation) 12 % 10 % 10 %”
$1.7B relationship
basisVTRS fy2025 · closed 2025-12 $14.3B
FILING10-K0001792044-25-000008cik 0001792044
“McKesson Corporation * 10 % 11 %”
$1.4B relationship28× more of VTRS’s book than MCK’s
basisVTRS fy2025 · closed 2025-12 $14.3BMCK fy2026 · closed 2026-03 $403B
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001792044-25-000008cik 0001792044
“Cardinal Health, Inc. * 5 % 5 %”
$715M relationship18× more of VTRS’s book than CAH’s
basisVTRS fy2025 · closed 2025-12 $14.3BCAH fy2026 · closed 2026-06 $254B
The two fiscal years close in different months, so the derived share compares periods that do not line up exactly.
FILING10-K0001792044-25-000008cik 0001792044
“While Viatris Inc. ("Viatris") records the total net sales of YUPELRI within its own financial statements, our implied 35% YUPELRI revenue, as compared to the prior year period, was as follows:”
$38M relationship133× more of TBPH’s book than VTRS’s
basisTBPH fy2025 · closed 2025-12 $107MVTRS fy2025 · closed 2025-12 $14.3B
FILING10-K0001104659-26-033077cik 0001583107disclosed by TBPH
“Viatris is responsible for any commercialization activities associated with any approved PS indications.”
FILING10-K0001140361-26-009247cik 0001228627disclosed by IRD
“Viatris is the NDA holder and is responsible for manufacturing, pricing and compliance matters as well as sales and marketing in the community setting.”
FILING10-K0001104659-26-033077cik 0001583107disclosed by TBPH
“A recent example of how the Company is utilizing its Global Healthcare Gateway® is the October 2024 exclusive licensing agreement with Lexicon for sotagliflozin in all markets outside of the U.S. and Europe.”
FILING10-K0001792044-25-000008cik 0001792044
“Under the terms of the original agreements, the development programs and certain personnel for selatogrel and cenerimod were transferred to Viatris from Idorsia in exchange for an upfront payment to Idorsia of $350 million, potential contingent milestone payments (including $300 million payable upon the achievement of certain development and regulatory milestones, and $2.1 billion payable upon the achievement of certain tiered sales milestones), as well as potential contingent tiered sales royalties.”
FILING10-K0001792044-25-000008cik 0001792044
“The decrease was primarily due to upfront licensing payments to Mapi of $75.0 million related to additional products under development recorded during the prior year.”
FILING10-K0001792044-25-000008cik 0001792044
“The decrease in other income, net was driven by: (1) higher net loss on divestitures of approximately $156.4 million, (2) charges of $184.6 million related to the impairment of our equity investment in Mapi and advances for GA Depot inventory (refer to Note 18 Licensing and Other Partner Agreements included in Part II, Item 8 of this Form 10-K for more information), (3) net gains recorded in the prior year of approximately $43.4 million as a result of remeasuring our equity interests in Mapi and Famy Life Sciences and the CCPS in Biocon Biologics to fair value, and (4) lower TSA income of approximately $98.1 million as the prior year included TSA income related to the reimbursement for transition services provided to Biocon Biologics.”
FILING10-K0001792044-25-000008cik 0001792044
“Viatris Pty Ltd., a subsidiary of Viatris Inc., for the commercialization of Twyneo and Epsolay in Australia and New Zealand.”
FILING20-F0001178913-26-001552cik 0001684693disclosed by SLGL
Watchlist prices, news filtered to it, and its next report on your desk.
Viatris Inc has 5 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Viatris Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
VTRS (Viatris Inc) has 5 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.